[Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer]

研究成果: Review article査読

抄録

Prostate cancer (PCa) is the most common cancer type in men. One of the most troublesome aspects of PCa is that androgen-dependent PCa inevitably progresses to highly aggressive and life-threatening castration resistant prostate cancer (CRPC). Kinases are key regulators of critical cancer processes such as cancer cell proliferation, invasion, differentiation or angiogenesis. Recent advances have shed light on molecular targeting inhibitors of kinases in CRPC. Aberrant expression of certain kinases has been implicated in the development and progression of PCa. Among them, some kinase inhibitors have emerged as promising drug targets for CRPC. In this review, we provide an overview of new therapeutic agents which arrived in an advanced stage of clinical testing, especially focusing on the targets of HGF/c-Met and PI3K/AKT/mTOR signaling pathways.

本文言語English
ページ(範囲)2186-2192
ページ数7
ジャーナルNihon rinsho. Japanese journal of clinical medicine
72
12
出版ステータスPublished - 2014 12 1
外部発表はい

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「[Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer]」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル